What we do
The PsoReal registry is a program of "outcomes research" on psoriasis in its various forms which originates from the PsoCare project coordinated in Italy by Centro Studi GISED from 2005 to 2010.
The PsoReal program involves:
The information will be collected by doctors and inserted into a web-based database. The information in the database will be updated on a biannual basis.
The following systemic agents will be specifically considered: acitretin, cyclosporine, methotrexate, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, apremilast. Brand products and generics or biosmilars will be separately considered.
The aim is to collect data on at least 1,500 patients and to follow them up for a minimum period of three years, describing the long-term outcome of different systemic treatments, and the benefits and risks of the medications employed, possibly identifying specific groups of patients at increased risk of adverse outcomes or lack of clinical benefit.
The study started on December 2015 with the participation of 17 centers in the Lombardy and Piedmont regions.
Back to research project